# FDA Approves Hope Pharmaceuticals' Sodium Thiosulfate Injection Hope Pharmaceuticals received FDA approval for sodium thiosulfate intravenous injection on February 14, 2012, marking an important addition to the company's portfolio in the critical care and specialty pharmaceutical markets. The approval positions Hope Pharmaceuticals to capture market share in the niche segment for antidote therapies, particularly for cyanide poisoning and other acute care applications.